Mr. Scott Cormack has more than two decades of experience in the biotechnology industry in executive management and venture capital. Scott has been President and CEO since August 2008, when OncoGenex Technologies Inc. completed a reverse takeover of Sonus Pharmaceuticals, Inc. to become OncoGenex Pharmaceuticals, Inc. Scott has led OncoGenex through significant corporate milestones, including private financings, leading the company from pre-clinical studies to completion of multiple Phase 2 clinical trials, initiation of Phase 3 trials and development of a robust pipeline. Scott was a co-founder of OncoGenex Technologies Inc., now a wholly owned subsidiary, where he served as President and a member of the Board of Directors since May 2000 and as Chief Executive Officer since February 2002. From 1998 to 2001, Scott served as Vice President of Milestone Medica Corporation, a seed venture capital firm investing in life sciences opportunities and joint venture between RBC Technology Ventures Inc. and Research Corporation Technologies. While at Milestone Medica, Scott served as interim President, Chief Executive Officer and Chairman of the Board of Directors of Salpep Biotechnology Inc., an asthma and inflammation biotechnology company, from 2000 to 2001. From 1995 to 1998, Scott served as Chief Operating Officer of NeuroSpheres Ltd, a neural stem cell biotechnology company. He was President and founder of For Tomorrow, a sole proprietorship engaged in business consulting, from 1991 to 1999. From 1986 to 1988, Scott served as Territory Manager of Vetrepharm Inc. (now Bioniche Life Sciences, Inc.), a biopharmaceutical company developing products for human and animal health markets, and from 1988 to 1991 he served as its Technology Manager, Immunomodulators. Scott holds a B.S. degree from the University of Alberta.